Navigation Links
The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients

the IMF, added, "These findings may also have wider implications for cancer treatments because they challenge the traditional notion that patients should be treated with the highest dose of medicine they can tolerate. Now we have evidence that in some situations, less may be more when treating cancer."

REVLIMID from the Celgene Corporation is the newest of the group of medicines called novel therapies that have significantly improved the outlook for patients with myeloma. Preliminary analysis of the ECOG data shows patients taking REVLIMID plus low dose dexamethasone had a 96% survival rate after one year with a reduced risk of side effects. One year survival for those taking the higher dose of dexamethasone was 86%. The findings are expected to prompt review of the dexamethasone dose when paired with other medications used in myeloma such as THALOMID(R), and discussions are already underway to change dosing in other clinical trials using REVLIMID with dexamethasone.

"This is a very exciting finding for patients," said Michael Katz, who, as a 16-year myeloma survivor, is a vice president of the IMF and co-chair of ECOG's Patient Representatives Committee. "When ECOG's patient representatives proposed adding a lower dose 'dex' arm to this trial, we were just looking for a way to make the treatment more tolerable; we never expected that the outcome for patients would actually improve. We are grateful to all of the patients who participated and to ECOG Group chair, Dr. Robert Comis and Myeloma Committee chair, Dr. Vincent Rajkumar, for supporting the notion of testing lower doses and making this trial happen."

Mr. Katz continued: "This result sends an important signal to physicians that maximum tolerated dose is not always the right answer when treating patients with cancers like myeloma that are incurable, but highly treatable."

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the nation,s ... Polaris Medical Imaging, a leader in sales, service and ... acquisition allows BC Technical to continue to expand their ... MR and CT modalities. "We are ... Mark Alvarez , president and CEO of BC ...
(Date:8/29/2014)... DENVER , Aug. 29, 2014 Does your ... date, nearly 800 doctors have recommended marijuana to the over ... Amendment 20. But the majority of the other roughly 20,300+ ... still know very little about it – even though a ... adults say they have tried it. ...
(Date:8/29/2014)... Diseases largely eradicated in the ... Measles was declared eliminated in 2000, yet the CDC ... 15—the highest incidence in 20 years. In July, ... cough a problem of "epidemic proportions." ... from these preventable diseases—in part because some parents (more ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... WESTON, Fla. , June 15 DHL Global Mail ... of mail-order pharmacies. DHL SMARTMAIL PHARMA SELECT ™ incorporates best ... the pharmaceutical industry. Thanks to this expertise and Global Mail,s nationwide ... accountability and value. , , ...
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President ... Goldman Sachs Global Healthcare Conference on Tuesday, June 15 , at ... in Los Angeles .  The presentation will be webcast on the ... , , ...
Cached Medicine Technology:DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies 2
(Date:8/31/2014)... August 31, 2014 This September, ... California State Library, celebrates 30 years of changing ... Since its inception, California’s Library Literacy Services has ... learn to read and write. , To mark ... the state is launching a month-long awareness campaign ...
(Date:8/31/2014)... Sunday 31 August 2014: Renal denervation seems to ... with resistant hypertension when it includes accessory renal arteries, ... Dr Linda Schmiedel from Germany. , Dr Schmiedel said: ... hypertension, which is defined as blood pressure (BP) greater ... from resistant hypertension (rHTN) and are unable to reduce ...
(Date:8/30/2014)... August 2014: A new method to predict the ... was presented at ESC Congress today by Dr Benjamin ... needs 350 AEDs located in public places for optimal ... Dr Dahan said: "Out of hospital cardiac arrest is ... ranging between 50 and 100 per 100 000 in ...
(Date:8/30/2014)... Walking-Canes.Net has released several articles related ... can help in making gait problems easier. The new ... website that contains all of the news articles that were ... articles deal with diseases that make walking a problem and ... help in making life easier for the patient. The articles ...
(Date:8/30/2014)... Cokato, MN (PRWEB) August 31, 2014 ... renewed in home renovation, especially spa style bathrooms and ... (NASS) has observed an increase in interest not ... understanding the history, culture and health benefits of sauna. ... Finnleo , the North American Sauna Society provides ...
Breaking Medicine News(10 mins):Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Renal denervation more successful when it includes accessory arteries 2Health News:New method predicts optimal number and location of AEDs 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2
... compared to kids without disorder , MONDAY, Oct. 19 ... in blood mercury levels between children who are developing ... disorders. , The findings, appearing online Oct. 19 in ... some of the debate surrounding mercury and autism. , ...
... not trained in skin cancer examinations, nor have they ever ... the October issue of Archives of Dermatology , one ... that can be detected early for which U.S. death rates ... Although melanoma remains the second most common cause of cancer ...
... WASHINGTON, D.C., October 19, 2009 With chronic diseases ... solutions to improve care and outcomes for these often ... today announced a new initiative funded with a grant ... will allow pediatricians across the country to pilot a ...
... a joint letter to the Centers for Medicare and ... fluorodeoxyglucose (FDG) positron emission tomography (PET) scans for a ... only one FDG-PET study during initial treatmenta limitation that ... under certain circumstances. "It is absolutely critical for ...
... ... Assara Laser Cosmetic Services Centers and Park Avenue Laser Vision ... dedication to providing exemplary care in the cutting-edge laser cosmetics field. ... laser spider vein removal and laser facials. Park Avenue Laser Vision ...
... ... Access, Choice, and Flexibility. , ... Albany, NY (Vocus) October 19, 2009 -- In a continuous effort to develop products and ... benefits, CDPHP ® announces several enhancements to take effect in 2010 pending New York ...
Cached Medicine News:Health News:Mercury Levels Not Abnormal in Autistic Children 2Health News:Mercury Levels Not Abnormal in Autistic Children 3Health News:Resident physicians seldom trained in skin cancer examination 2Health News:Pediatricians put proven treatment strategies to work against childhood asthma 2Health News:1 scan per patient is not always enough 2Health News:Assara Laser Announces Strategic Alliance with Park Avenue Laser Vision 2Health News:Assara Laser Announces Strategic Alliance with Park Avenue Laser Vision 3Health News:CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives 2Health News:CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives 3Health News:CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives 4
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
The Multi-Purpose Medical-Surgical Shoe...
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... For use as a non-reactive quality assurance reagent ... Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG ... and rubella IgM), IgG and IgM antibodies to ... IgM antibodies to herpes simplex virus types 1 ...
Medicine Products: